Neisseria meningitidis Resistance to Antibiotics Remains Rare in the U.S.

N. meningitidis isolates from invasive disease cases showed no resistance to cefotaxime, ceftriaxone, or rifampin — although nearly one third showed reduced susceptibility to penicillin.

The incidence of invasive meningococcal disease (IMD) has declined in the U.S. but still carries a mortality of nearly 16%. Antibiotic management includes both treatment with empiric ceftriaxone or cefotaxime and prevention using rifampin, ciprofloxacin, or ceftriaxone. Although uncommon, multiple phenotypes characterized by reduced antibiotic susceptibility have been reported; nonetheless, recent surveys capturing these are lacking. To identify confirmed cases of IMD in the U.S., CDC investigators used two databases: The Active Bacterial Core Surveillance system (ABCs), consisting of information from 2012–2016 on 44 million persons, and the Enhanced Meningococcal Diseases Surveillance (EMDS), including data from 2015–2016 on 98% of the pop…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neisseria meningitidis Resistance to Antibiotics Remains Rare in the U.S.

Topics

Reviewing Author